Expanded Pediatric Use for Roflumilast Under FDA Review

If approved, topical roflumilast 0.05% will be approved for treating atopic dermatitis down to age 3 months.
Medscape Medical News

source https://www.medscape.com/viewarticle/expanded-pediatric-indication-topical-roflumilast-under-fda-2026a1000ndq?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors